title: Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men: lack of antagonism by flumazenil.
abstract: The role of melatonin in the regulation of human reproduction remains unclear. In the present study, we examined the influence of exogenous melatonin on pulsatile luteinizing hormone (LH), diurnal rhythm of testosterone, and endogenous melatonin profile in six healthy young adult males. To test the hypothesis that the effect of melatonin on LH or testosterone secretory patterns may be mediated through the benzodiazepine-(BNZ) gamma-amino-butyric acid (GABA) receptor complex, a benzodiazepine receptor antagonist (Flumazenil) was administered. The study design comprised four 10-h (4:00 PM-2:00 AM) testing periods. During each experimental period, subjects were given an oral dose of placebo, or 3 mg melatonin or 10 mg flumazenil, at 5:00 PM, in a randomized, double-blind, partially repeated Latin square design in the following combinations: placebo-placebo, placebo-melatonin, flumazenil-placebo, and flumazenil-melatonin. The following day, serum samples were obtained every 20 min between 4:00 PM and 2:00 AM in a controlled light-dark environment for the determination of LH and melatonin levels. Serum testosterone concentrations were determined every 20 min between 7:00 and 8:00 AM and 7:00 and 8:00 PM. A significant decrease in mean serum LH levels (p < 0.02) was observed in the melatonin-treated groups as compared with placebo-flumazenil groups. There was no change in LH pulse frequency, testosterone levels, or in melatonin onset time and amplitude. No additional effect of flumazenil on LH or testosterone levels was observed. These data indicate that an evening melatonin administration decreases the next-day LH secretion in normal adult males without altering testosterone levels or the endogenous nocturnal melatonin secretory pattern. This effect of melatonin is not mediated through the benzodiazepine-GABA receptor complex.
authors.affiliation: Endocrine Institute, Haemek Medical Center, Afula, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Luboshitzky
authors.forename: Z
authors.initials: Z
authors.lastname: Shen-Orr
authors.forename: T
authors.initials: T
authors.lastname: Shochat
authors.forename: P
authors.initials: P
authors.lastname: Herer
authors.forename: P
authors.initials: P
authors.lastname: Lavie
mesh_terms: D000328:Adult; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D004311:Double-Blind Method; D005442:Flumazenil / Q000494:pharmacology*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood* / Q000378:metabolism; D008297:Male; D008550:Melatonin / Q000037:antagonists & inhibitors / Q000097:blood / Q000494:pharmacology*; D010919:Placebos; D013739:Testosterone / Q000097:blood
chemical_list: D010919:Placebos; D013739:Testosterone; D005442:Flumazenil; D007986:Luteinizing Hormone; D008550:Melatonin